ObeEnd - Pioneering Drug-Free Weight Management Wristband
According to the
While medical interventions for weight loss exist, such as surgical procedures or pharmaceuticals like the FDA-approved Wegovy (semaglutide injection), these options often present significant drawbacks including adverse side effects, inconsistent outcomes, and challenges in sustaining weight loss post-treatment cessation. Studies have shown that discontinuing semaglutide injections can lead to rapid weight regain, underscoring the need for alternative solutions.
WAT Medical's mission is to offer a safe and effective alternative for weight management, and ObeEnd represents a paradigm shift in this pursuit. Leveraging neuromodulation technology, ObeEnd delivers targeted electrical impulses via PC6 to mitigate gastric secretion while enhancing post-exercise recovery. Clinical studies have demonstrated that ObeEnd results in significant reduction in caloric intake and pepsinogen-1 production. The mechanism underlying ObeEnd's efficacy is believed to be sympathetic inhibition, which have also demonstrated efficacy in alleviating symptoms of nausea, vomiting, and even reducing blood pressure levels.
The encouraging clinical results of ObeEnd mark a significant milestone towards the realization of an innovative, drug-free wearable solution for weight management. Ongoing clinical studies, conducted in collaboration with
For further information on ObeEnd and WAT Medical's pioneering efforts in healthcare innovation, please visit watmedical.com.
References
[1]
[3] https://www.cdc.gov/obesity/data/adult.html
View original content to download multimedia:https://www.prnewswire.com/news-releases/obeend---pioneering-drug-free-weight-management-wristband-302143248.html
SOURCE